Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

4 clinical studies listed.

Filters:

Chemotherapy-Related Cognitive Impairment

Tundra lists 4 Chemotherapy-Related Cognitive Impairment clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ACTIVE NOT RECRUITING

NCT05283629

nCCR for Chemotherapy Related Cognitive Impairment Randomized Study

The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to treat chemotherapy-related cognitive impairment (CRCI).

Gender: All

Ages: 35 Years - 80 Years

Updated: 2026-01-08

1 state

Chemo-brain
Chemotherapy-Related Cognitive Impairment
NOT YET RECRUITING

NCT06508671

Effects of DL-3-n-butylphthalide on Chemotherapy-Induced Cognitive Impairment

Chemotherapy-related cognitive Impairment (CICI) is a series of neurocognitive deficits experienced during and after cancer chemotherapy. Studies have reported that CICI affects 25% to 75% of survivors and can persist for years after chemotherapy is discontinued, causing more severe progressive manifestations and placing a heavy burden on families and society. Numerous studies have proposed several potential mechanisms and etiologies for CICI, including direct neurotoxicity, disruption of the blood-brain barrier, reduced hippocampal neurogenesis, white matter abnormalities, secondary neuroinflammatory responses, and increased oxidative stress. At present, there is no clear and effective diagnosis and therapy for CICI, and how to diagnose and treat cognitive impairment caused by chemotherapy effectively is still the focus and difficulty. Based on the previous consensus on the application of dl-3-n-butylphthalide, butylphthalein can play a neuroprotective role by reducing oxidative stress and inflammatory response, inhibiting neuronal apoptosis, improving mitochondrial function and other mechanisms, and significantly improve the performance of the central nervous system caused by cerebral ischemia and vascular dementia. However, the increase of neuroinflammatory response and oxidative stress is precisely one of the potential mechanisms of CICI pathogenesis. Therefore, based on the above findings, this study hypothesized that dl-3-n-butylphthalide would also have considerable efficacy in the treatment of CICI.

Gender: All

Ages: 35 Years - 80 Years

Updated: 2024-07-18

Chemotherapy-Related Cognitive Impairment
DL-3-n-butylphthalide
NOT YET RECRUITING

NCT06234150

Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment

The goal of this clinical trial is to learn about breast cancer patients. The main questions it aims to answer are: * Does Aerobic Dance During Chemotherapy Improve Cognitive Function in Breast Cancer Patients? * Does the efficacy of aerobic dance differ from fast walking of equal intensity? Recruited patients will be randomly assigned to three groups: (1) aerobic dance group, (2) fast walking group, and (3) usual care group. The aerobic dance and fast-walking groups participated in supervised exercise lasting 50 minutes thrice a week for 12 weeks. The goal of this study's findings is to develop practical strategies for managing breast cancer-related cognitive impairment.

Gender: FEMALE

Ages: 18 Years - 65 Years

Updated: 2024-02-20

1 state

Breast Neoplasms
Exercise Therapy
Chemotherapy-Related Cognitive Impairment
+2
RECRUITING

NCT05840575

Investigating Cognitive Impairment in Young Patients With Cancer Prospectively

The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer. The tests include 1) cognitive skills such as memory and attention; 2) the brain's electrical activity; 3) and biological markers related to brain function. The aim of the study is to better understand the trajectories of cognitive functioning and measures that have been associated with cognitive impairment in patients treated with chemotherapy.

Gender: All

Ages: 7 Years - 29 Years

Updated: 2023-05-03

Chemotherapy-Related Cognitive Impairment
Chemotherapeutic Toxicity
Chemo-brain
+7